[go: up one dir, main page]

NO20072366L - Anti-glypikan antistoff med modifisert sukkerkjede - Google Patents

Anti-glypikan antistoff med modifisert sukkerkjede

Info

Publication number
NO20072366L
NO20072366L NO20072366A NO20072366A NO20072366L NO 20072366 L NO20072366 L NO 20072366L NO 20072366 A NO20072366 A NO 20072366A NO 20072366 A NO20072366 A NO 20072366A NO 20072366 L NO20072366 L NO 20072366L
Authority
NO
Norway
Prior art keywords
glypican
antibody
modified sugar
sugar chain
fucose
Prior art date
Application number
NO20072366A
Other languages
English (en)
Norwegian (no)
Inventor
Kiyotaka Nakano
Megumi Tanaka
Izumi Sugo
Takahiro Ishiguro
Masamichi Sugimoto
Shigeyuki Iijima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20072366L publication Critical patent/NO20072366L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20072366A 2004-10-26 2007-05-09 Anti-glypikan antistoff med modifisert sukkerkjede NO20072366L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26
PCT/JP2005/020057 WO2006046751A1 (fr) 2004-10-26 2005-10-26 Anticorps anti-glypicane 3 à chaîne sucrée modifiée

Publications (1)

Publication Number Publication Date
NO20072366L true NO20072366L (no) 2007-06-21

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072366A NO20072366L (no) 2004-10-26 2007-05-09 Anti-glypikan antistoff med modifisert sukkerkjede

Country Status (19)

Country Link
US (2) US7867734B2 (fr)
EP (1) EP1816140A4 (fr)
JP (1) JP4794457B2 (fr)
KR (1) KR101296931B1 (fr)
CN (1) CN101068836B (fr)
AU (1) AU2005297772B2 (fr)
BR (1) BRPI0518279A2 (fr)
CA (1) CA2585196C (fr)
CR (1) CR9151A (fr)
IL (1) IL182662A (fr)
MA (1) MA29025B1 (fr)
MX (1) MX2007004593A (fr)
NO (1) NO20072366L (fr)
NZ (1) NZ554940A (fr)
RU (1) RU2451030C2 (fr)
TW (1) TWI468514B (fr)
UA (1) UA93488C2 (fr)
WO (1) WO2006046751A1 (fr)
ZA (1) ZA200703888B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
EP2228445A1 (fr) * 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Transporteur du fucose
CN102702353A (zh) * 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
ES2422898T3 (es) * 2004-08-24 2013-09-16 Chugai Seiyaku Kabushiki Kaisha Terapia adyuvante con el uso de anticuerpo anti-glipicano 3
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
HUE028737T2 (en) 2007-07-17 2017-01-30 Squibb & Sons Llc Monoclonal antibodies against glypican-3
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
CN101809162B (zh) 2007-09-28 2013-06-05 中外制药株式会社 血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
US8023425B2 (en) 2009-01-28 2011-09-20 Headwater Partners I Verifiable service billing for intermediate networking devices
US12452377B2 (en) 2009-01-28 2025-10-21 Headwater Research Llc Service design center for device assisted services
US12543031B2 (en) 2009-01-28 2026-02-03 Headwater Research Llc Adapting network policies based on device service processor configuration
US12166596B2 (en) 2009-01-28 2024-12-10 Disney Enterprises, Inc. Device-assisted services for protecting network capacity
US11985155B2 (en) 2009-01-28 2024-05-14 Headwater Research Llc Communications device with secure data path processing agents
US12389218B2 (en) 2009-01-28 2025-08-12 Headwater Research Llc Service selection set publishing to device agent with on-device service selection
WO2012123755A1 (fr) 2011-03-17 2012-09-20 The University Of Birmingham Immunothérapie redirigée
EP3557260B1 (fr) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN106029870A (zh) * 2014-01-16 2016-10-12 凯利斯塔公司 用于增强的氨基酸产生的微生物及相关方法
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017002934A1 (fr) 2015-07-01 2017-01-05 中外製薬株式会社 Agent thérapeutique à gpc3 ciblé administré à un patient dans lequel un agent thérapeutiques à gpc3 ciblé est déterminé comme étant efficace
EP3333192B1 (fr) * 2015-08-03 2021-05-19 Cafa Therapeutics Limited Anticorps dirigé contre le glypican-3 et application associée
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
BR112018015259A2 (pt) 2016-01-27 2018-12-18 Medimmune Llc métodos para preparação de anticorpos com um padrão de glicosilação definido
WO2017159699A1 (fr) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Procédés de traitement de cancers au moyen d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-gpc3
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
EP3502250B1 (fr) 2016-08-22 2024-04-24 Chugai Seiyaku Kabushiki Kaisha Rongeurs génétiquement modifiés exprimant un polypeptide gpc3 humain
CN106591371A (zh) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
CN113272016A (zh) 2018-10-01 2021-08-17 阿迪塞特生物股份有限公司 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
EP3976104A4 (fr) 2019-05-24 2023-10-04 Elixiron Immunotherapeutics (Hong Kong) Limited Anticorps anti-csf1r, protéines de fusion il10 et leurs utilisations
AU2020288499A1 (en) 2019-06-05 2022-01-27 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
JP2023518930A (ja) * 2020-03-18 2023-05-09 ユーティレックス カンパニー リミテッド Ｇｐｃ３ ｃａｒ－ｔ細胞組成物、並びにそれを作製する方法及び使用する方法
US20240301085A1 (en) * 2021-02-10 2024-09-12 Simcere Zaiming Pharmaceutical Co., Ltd. Humanized gpc3 antibody and application thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
ATE297219T1 (de) * 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
IL135221A0 (en) * 1997-10-03 2001-05-20 Chugai Pharmaceutical Co Ltd Natural humanized antibody and methods for the preparation thereof
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2601882T5 (es) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
JP5059279B2 (ja) 2000-09-12 2012-10-24 ユニオン カーバイド ケミカルズ アンド プラスティックス テクノロジー エルエルシー アルキレンオキシドコポリマーを含むポリマー複合材
HU231090B1 (hu) * 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
AU2002315857B2 (en) * 2001-06-22 2007-07-26 Kaisha, Chugai Seiyaku Kabushiki Cell proliferation inhibitors containing anti-glypican 3 antibody
EP1423510A4 (fr) * 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
WO2003042686A1 (fr) 2001-11-14 2003-05-22 Kabushiki Kaisha Toshiba Echographe, transducteur ultrasons, instrument d'examen et dispositif d'ultrasonographie
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
EP1464702A4 (fr) * 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd Procede de stabilisation d'une proteine
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2003085119A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
PT1506406E (pt) * 2002-05-23 2009-06-03 Sunnybrook Health Sciences Ct Diagnóstico de carcinoma hepatocelular
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
WO2004022595A1 (fr) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Elaboration d'un anticorps utilisant une souris mrl/1pr
WO2004023145A1 (fr) 2002-09-04 2004-03-18 Perseus Proteomics Inc. Procede de detection du cancer par detection du gpc3
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005023301A1 (fr) 2003-09-04 2005-03-17 Chugai Seiyaku Kabushiki Kaisha Remede et medicament de detection pour le cancer des voies biliaires
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
CN102702353A (zh) * 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
EP1778359B1 (fr) * 2004-08-08 2010-10-13 KHAYAT, Eli Compositions pharmaceutiques permettant d'attenuer les niveaux excessifs de sucre chez les patients diabetiques
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
ES2422898T3 (es) 2004-08-24 2013-09-16 Chugai Seiyaku Kabushiki Kaisha Terapia adyuvante con el uso de anticuerpo anti-glipicano 3
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
DK2202245T3 (en) * 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
KR20110005812A (ko) * 2008-03-17 2011-01-19 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
CN101068836A (zh) 2007-11-07
EP1816140A1 (fr) 2007-08-08
KR20070070222A (ko) 2007-07-03
MA29025B1 (fr) 2007-11-01
MX2007004593A (es) 2007-06-22
CA2585196A1 (fr) 2006-05-04
US20080124330A1 (en) 2008-05-29
RU2007119579A (ru) 2008-12-10
JP4794457B2 (ja) 2011-10-19
TWI468514B (zh) 2015-01-11
RU2451030C2 (ru) 2012-05-20
NZ554940A (en) 2010-04-30
AU2005297772B2 (en) 2011-06-23
UA93488C2 (uk) 2011-02-25
HK1110335A1 (en) 2008-07-11
EP1816140A4 (fr) 2009-09-02
TW200621980A (en) 2006-07-01
JPWO2006046751A1 (ja) 2008-05-22
CA2585196C (fr) 2015-01-06
WO2006046751A1 (fr) 2006-05-04
CR9151A (es) 2008-03-18
ZA200703888B (en) 2009-11-25
BRPI0518279A2 (pt) 2008-11-11
KR101296931B1 (ko) 2013-08-14
IL182662A (en) 2014-09-30
CN101068836B (zh) 2013-08-14
IL182662A0 (en) 2007-09-20
US7867734B2 (en) 2011-01-11
AU2005297772A1 (en) 2006-05-04
US20110033452A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
NO20072366L (no) Anti-glypikan antistoff med modifisert sukkerkjede
WO2009080743A3 (fr) Plantes à rendement accru (ko nue)
EP1546174A4 (fr) Methodes et compositions d'interference arn
WO2004065546A3 (fr) Compositions et procedes destines a l'inhibition du gene icam-1 par arn a faible inhibition
WO2006097320A3 (fr) Liaisons nucleotidiques macromoleculaires et procedes d'utilisation associes
WO2005095618A3 (fr) Plantes presentant une activite reduite de l'enzyme de phosphorylation de l'amidon
WO2006026408A3 (fr) Production d'$g(a)-abeta
DE602004012881D1 (en) Cst (compartmentalised self tagging)
MX2009009371A (es) Produccion mejorada de derivados de acidos grasos.
WO2007027509A3 (fr) Evaluation et traitement de la sclerodermie
RU2009145502A (ru) Одноцепочечная кольцевая рнк и способ ее получения
WO2011005860A3 (fr) Mimétiques de 5' phosphate
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
BR112012012100A2 (pt) método para o tratamento de água dentro um reator biológico sequencial incluindo uma medição em linha da concentração de nitrito dentro do referido reator
WO2006099258A8 (fr) Compositions de tigecycline et leurs methodes de preparation
NO20075865L (no) Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme
WO2006022664A3 (fr) Alanine 2, 3 aminomutases
WO2005033287A3 (fr) Methodes d'identification d'un produit genique a voie de synthese biologique
WO2007118751A3 (fr) Procédé de modification du rapport atp/adp dans des cellules
EP2184609A3 (fr) Compositions et méthodes pour traiter le cancer du poumon
WO2013059203A8 (fr) Nouvelles curcumines modifiées et leurs utilisations
WO2007089732A3 (fr) Amélioration des niveaux et/ou de la durabilité de l'expression génique à base d'adn
WO2006015887A3 (fr) Modulation de biosynthèse alcaloïdique des plantes et plantes à biosynthèse alcaloïdique altérée
WO2005090572A3 (fr) Compositions et procédés servant à traiter un cancer du pancréas
WO2002090619A3 (fr) Produit d'addition, preparation et utilisation dudit produit en tant qu'inhibiteur de corrosion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application